DRUG SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Bright Minds Biosciences
Investors who lost money when DRUG shares sold off on the FDA's partial clinical hold for the planned Phase 2 BMB-101 epilepsy trial may have the right to seek recovery, even if they have already sold. NEW YORK, Nov. 3, 2026 /PRNewswire/ -- Shareholders of Bright Minds Biosciences...
Covered in this story
Call it yourself
No calls on $NOV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on NOV →Dalsna Finance is currently tracking 167 stories mentioning NOV, the earliest published 27 Oct 2026.
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.